ZA200405657B - Formulation & dosage form for the controlled delivery of therapeutic agents. - Google Patents
Formulation & dosage form for the controlled delivery of therapeutic agents.Info
- Publication number
- ZA200405657B ZA200405657B ZA200405657A ZA200405657A ZA200405657B ZA 200405657 B ZA200405657 B ZA 200405657B ZA 200405657 A ZA200405657 A ZA 200405657A ZA 200405657 A ZA200405657 A ZA 200405657A ZA 200405657 B ZA200405657 B ZA 200405657B
- Authority
- ZA
- South Africa
- Prior art keywords
- formulation
- dosage form
- therapeutic agents
- controlled delivery
- delivery
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34300101P | 2001-12-19 | 2001-12-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200405657B true ZA200405657B (en) | 2005-08-29 |
Family
ID=23344252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200405657A ZA200405657B (en) | 2001-12-19 | 2004-07-15 | Formulation & dosage form for the controlled delivery of therapeutic agents. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20030232078A1 (de) |
EP (1) | EP1458353A1 (de) |
JP (1) | JP2005513095A (de) |
KR (1) | KR20040090961A (de) |
CN (1) | CN1620281A (de) |
AU (1) | AU2002357930B2 (de) |
CA (1) | CA2471081A1 (de) |
HU (1) | HUP0402661A3 (de) |
IL (1) | IL162294A0 (de) |
MX (1) | MXPA04006025A (de) |
NO (1) | NO20042993L (de) |
NZ (1) | NZ533062A (de) |
WO (1) | WO2003053400A1 (de) |
ZA (1) | ZA200405657B (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020141970A1 (en) * | 2001-03-05 | 2002-10-03 | Pettit Dean K. | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
NZ534738A (en) * | 2002-02-25 | 2007-01-26 | Lyfjathroun Hf | Absorption enhancing agent |
KR100897890B1 (ko) | 2002-06-17 | 2009-05-18 | 인벤티아 헬스케어 피브이티. 엘티디. | 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법 |
MXPA05000206A (es) * | 2002-06-28 | 2005-12-05 | Johnson & Johnson | Forma de dosificiacion oral que comprende una formulacion liquida de agente activo y liberacion controlada de la misma mediante una composicion osmotica expansible. |
US6855332B2 (en) * | 2002-07-03 | 2005-02-15 | Lyfjathroun Hf. | Absorption promoting agent |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
US20040142040A1 (en) * | 2002-10-31 | 2004-07-22 | Dong Liang C. | Formulation and dosage form providing increased bioavailability of hydrophobic drugs |
US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
GB0308732D0 (en) * | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
GB0308734D0 (en) * | 2003-04-15 | 2003-05-21 | Axcess Ltd | Uptake of macromolecules |
EP1648409A2 (de) * | 2003-07-31 | 2006-04-26 | Alza Corporation | Permeationsfester osmotischer antrieb und dosierform für die kontrollierte freisetzung einer flüssigen wirkstoff-formulierung |
US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
US20050070608A1 (en) * | 2003-08-29 | 2005-03-31 | Julius Remenar | Pharmaceutical compositions and method of using levodopa and carbidopa |
CA2540059C (en) * | 2003-09-26 | 2013-08-06 | Alza Corporation | Controlled release formulations exhibiting an ascending rate of release |
KR20060070575A (ko) * | 2003-09-26 | 2006-06-23 | 알자 코포레이션 | 활성성분 제제의 방출제어용 제형 |
EP1667652B1 (de) * | 2003-09-26 | 2007-05-30 | ALZA Corporation | Verbesserte dosierform mit kontrollierter freisetzung mit stehantrieb |
ATE544447T1 (de) | 2003-09-26 | 2012-02-15 | Alza Corp | Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung |
JP2007509971A (ja) * | 2003-10-31 | 2007-04-19 | アルザ・コーポレーシヨン | メトホルミンの増加された吸収のための組成物及び投与形態物 |
US20050256097A1 (en) * | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
US20060045865A1 (en) * | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
AU2007284759B2 (en) | 2006-08-09 | 2010-10-28 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies |
RU2440097C2 (ru) | 2007-04-23 | 2012-01-20 | Интарсия Терапьютикс, Инк. | Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления |
US8789536B2 (en) | 2007-10-17 | 2014-07-29 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8707964B2 (en) | 2007-10-31 | 2014-04-29 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8303573B2 (en) | 2007-10-17 | 2012-11-06 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8808276B2 (en) | 2007-10-23 | 2014-08-19 | The Invention Science Fund I, Llc | Adaptive dispensation in a digestive tract |
US8333754B2 (en) | 2007-10-31 | 2012-12-18 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8808271B2 (en) | 2007-10-31 | 2014-08-19 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
US8109920B2 (en) * | 2007-10-31 | 2012-02-07 | The Invention Science Fund I, Llc | Medical or veterinary digestive tract utilization systems and methods |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
CN102143841A (zh) * | 2008-09-10 | 2011-08-03 | 西列坡斯股份有限公司 | 凝胶状弹性体组合物 |
JP5731396B2 (ja) | 2008-12-22 | 2015-06-10 | アラガン,インコーポレイティド | 鼻腔内デスモプレシン投与 |
MX343193B (es) | 2009-06-18 | 2016-10-26 | Allergan Inc | Administracion segura de desmopresina. |
EP3735944A1 (de) | 2009-09-28 | 2020-11-11 | Intarcia Therapeutics, Inc. | Schnelle initiierung und/oder beendigung der verabreichung substantiell stabiler arzneimittel |
US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US9622981B2 (en) | 2011-11-17 | 2017-04-18 | Mylan Inc. | Liquid-filled hard gel capsule pharmaceutical formulations |
US9789071B2 (en) | 2012-06-27 | 2017-10-17 | G2B Pharma, Inc. | Intranasal formulation of epinephrine for the treatment of anaphylaxis |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
MA44390A (fr) | 2015-06-03 | 2019-01-23 | Intarcia Therapeutics Inc | Systèmes de mise en place et de retrait d'implant |
WO2017200943A1 (en) | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
IL267736B2 (en) | 2017-01-03 | 2024-03-01 | Intarcia Therapeutics Inc | Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
WO2021176361A1 (en) * | 2020-03-02 | 2021-09-10 | Craft Health Pte Ltd | Method of manufacturing oral dosage forms for extended drug release |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2799241A (en) * | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (de) * | 1960-11-29 | |||
US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
US3546142A (en) * | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) * | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US3865108A (en) * | 1971-05-17 | 1975-02-11 | Ortho Pharma Corp | Expandable drug delivery device |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4002173A (en) * | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4207893A (en) * | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
US4627851A (en) * | 1984-10-26 | 1986-12-09 | Alza Corporation | Colonic-therapeutic delivery system |
US4915949A (en) * | 1987-07-13 | 1990-04-10 | Alza Corporation | Dispenser with movable matrix comprising a plurality of tiny pills |
US4931285A (en) * | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
US5024842A (en) * | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
US5160743A (en) * | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US5006346A (en) * | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US5126142A (en) * | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
US5178866A (en) * | 1990-03-23 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug to the intestine |
US5324280A (en) * | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5190765A (en) * | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
US5234280B2 (en) * | 1992-03-30 | 1997-12-09 | Plastic Safety Systems Inc | Traffic channeling devices |
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
US5633011A (en) * | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
US5637319A (en) * | 1995-03-01 | 1997-06-10 | Takada; Kanji | Controlled-release preparations |
US5998598A (en) * | 1997-03-10 | 1999-12-07 | The United States Of America, As Represented By The Department Of Health And Human Services | Immunoadhesins and methods of production and use thereof |
US6174547B1 (en) * | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
CA2354472C (en) * | 1998-12-17 | 2009-02-24 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
-
2002
- 2002-12-19 US US10/324,239 patent/US20030232078A1/en not_active Abandoned
- 2002-12-19 EP EP02792477A patent/EP1458353A1/de not_active Withdrawn
- 2002-12-19 MX MXPA04006025A patent/MXPA04006025A/es not_active Application Discontinuation
- 2002-12-19 CN CNA028280997A patent/CN1620281A/zh active Pending
- 2002-12-19 KR KR10-2004-7009709A patent/KR20040090961A/ko not_active Application Discontinuation
- 2002-12-19 IL IL16229402A patent/IL162294A0/xx unknown
- 2002-12-19 AU AU2002357930A patent/AU2002357930B2/en not_active Ceased
- 2002-12-19 HU HU0402661A patent/HUP0402661A3/hu unknown
- 2002-12-19 JP JP2003554159A patent/JP2005513095A/ja not_active Withdrawn
- 2002-12-19 CA CA002471081A patent/CA2471081A1/en not_active Abandoned
- 2002-12-19 NZ NZ533062A patent/NZ533062A/xx not_active IP Right Cessation
- 2002-12-19 WO PCT/US2002/040763 patent/WO2003053400A1/en active IP Right Grant
-
2004
- 2004-07-13 NO NO20042993A patent/NO20042993L/no not_active Application Discontinuation
- 2004-07-15 ZA ZA200405657A patent/ZA200405657B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL162294A0 (en) | 2005-11-20 |
AU2002357930B2 (en) | 2007-06-28 |
EP1458353A1 (de) | 2004-09-22 |
WO2003053400A1 (en) | 2003-07-03 |
HUP0402661A3 (en) | 2008-04-28 |
KR20040090961A (ko) | 2004-10-27 |
MXPA04006025A (es) | 2005-03-31 |
NZ533062A (en) | 2006-03-31 |
NO20042993L (no) | 2004-09-20 |
AU2002357930A1 (en) | 2003-07-09 |
CA2471081A1 (en) | 2003-07-03 |
CN1620281A (zh) | 2005-05-25 |
JP2005513095A (ja) | 2005-05-12 |
US20030232078A1 (en) | 2003-12-18 |
HUP0402661A2 (hu) | 2005-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200405657B (en) | Formulation & dosage form for the controlled delivery of therapeutic agents. | |
EP1416884A4 (de) | Abgabe von mitteln mit therapeutischen eigenschaften | |
IL196301A0 (en) | Medicament for the treatment of hapatitis c | |
IL157771A0 (en) | Intravaginal drug delivery devices for the administration of an antimicrobial agent | |
GB0117618D0 (en) | Pharmaceutical dosage form | |
MXPA03006775A (es) | Formulacion farmaceutica. | |
AP2004002982A0 (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain. | |
HK1073997A1 (en) | Administration of agents for the treatment of inflammation | |
IL219397A0 (en) | Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same | |
WO2002070438A3 (en) | Compositions for delivering bisphosphonates | |
MXPA03007641A (es) | Formulacion farmaceutica. | |
GB0117619D0 (en) | Pharmaceutical dosage form | |
NO20042208L (no) | Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter | |
MXPA03007857A (es) | Compuestos y composiciones para entregar agentes activos. | |
IL164896A (en) | Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors | |
MXPA03006526A (es) | Composicion farmaceutica que contiene compuestos de aminoacetonitrilo y su uso para la preparacion de una composicion farmaceutica para el tratamiento de plagas endoparasitarias en animales. | |
EP1406493A4 (de) | Verabreichung von mitteln über den pept-2-transporter | |
HUP0500638A3 (en) | Flashmelt oral dosage formulation | |
IL159576A0 (en) | Pharmaceutical formulation for the intramuscular administration of fulvestrant | |
HUP0204448A3 (en) | Trnasdermal therapeutic system for the delivery of lerisetron | |
HUP0102159A3 (en) | Pharmaceutical composition for the treatment of rumen acidosis | |
IL158587A0 (en) | Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof | |
EP1361866A4 (de) | Emulsionen als feste dosierformen für die orale verabreichung | |
HUP0200253A2 (en) | Pharmaceutical compositions for combination therapy | |
AU2002348105A1 (en) | Oral dosage forms for improving the bioavailability of therapeutic agents |